TNXP (Tonix Pharmaceuticals Holding) Other Current Receivables: $3.86 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TNXP Tonix Pharmaceuticals Holding Corp TNXP
39 GF Score
Price $12.42
GF Value $1.75
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Tonix Pharmaceuticals Holding Other Current Receivables?

Tonix Pharmaceuticals Holding TNXP +4.63% 39 Other Current Receivables is $3.86 Mil as of Mar. 2026. GuruFocus rates TNXP with a GF Score™ of 39/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Tonix Pharmaceuticals Holding's Other Current Receivables for the quarter that ended in Mar. 2026 was $3.86 Mil.

Tonix Pharmaceuticals Holding's quarterly Other Current Receivables increased from Sep. 2025 ($3.19 Mil) to Dec. 2025 ($4.05 Mil) but then stayed the same from Dec. 2025 ($4.05 Mil) to Mar. 2026 ($3.86 Mil).

Tonix Pharmaceuticals Holding's annual Other Current Receivables declined from Dec. 2023 ($6.10 Mil) to Dec. 2024 ($4.97 Mil) and declined from Dec. 2024 ($4.97 Mil) to Dec. 2025 ($4.05 Mil).

Tonix Pharmaceuticals Holding Other Current Receivables Related Terms

Tonix Pharmaceuticals Holding Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Tonix Pharmaceuticals Holding's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonix Pharmaceuticals Holding Other Current Receivables Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.73 8.04 6.10 4.97 4.05

Tonix Pharmaceuticals Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 5.55 3.19 4.05 3.86
TNXP
39GF Score
Tonix Pharmaceuticals Holding Corp TNXP
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tonix Pharmaceuticals Holding Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $3.86 Mil mean?
Tonix Pharmaceuticals Holding (TNXP) has a Other Current Receivables of $3.86 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Tonix Pharmaceuticals Holding and its competitors.
Is Tonix Pharmaceuticals Holding's Other Current Receivables too high?
Tonix Pharmaceuticals Holding's current Other Current Receivables is $3.86 Mil. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Other Current Receivables compare to ALEC and IMUX?
Tonix Pharmaceuticals Holding's Other Current Receivables of $3.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Tonix Pharmaceuticals Holding and its competitors. Tonix Pharmaceuticals Holding's current Other Current Receivables is $3.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $12.42 — trading 609.7% above its estimated fair value. The current Other Current Receivables is $3.86 Mil. Tonix Pharmaceuticals Holding's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current Other Current Receivables is $3.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?

Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued. The current stock price of $12.42 is trading 609.7% above its estimated GF Value™ of $1.75. GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.

Key valuation signals for TNXP:

  • Other Current Receivables: $3.86 Mil
  • GF Value™: $1.75 vs. price of $12.42 (609.7% above fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tonix Pharmaceuticals Holding Business Description

Other Exchanges TPM0:Germany
Address 200 Connell Drive, Suite 3100, Berkeley Heights, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
39GF Score

Get the complete analysis for TNXP

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.42
Price
$1.75
GF Value